ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction

Inclusion criteria

• Age ≥18 and <75 years;
• First-time acute anterior STEMI;
• The time from onset of ischemic symptom to the time of initial PCI balloon inflation ≤6 hours;
• >0.1 mV ST segment elevation in at least two contiguous precordial leads according to electrocardiogram;
• Scheduled for primary PCI;
• The presence of left anterior descending branch (LAD) occlusion in proximal or middle segment with pre-PCI TIMI flow 0 or 1 according to baseline coronary angiogram;
• Written informed consent.

Exclusion criteria

• Hypertrophic cardiomyopathy, aortic valve stenosis and/or regurgitation, pericarditis, or myocarditis;
• Cardiogenic shock, severe ventricular arrhythmia, serious heart failure (Killip class III and above) or mechanical complications;
• Patients after cardiopulmonary resuscitation (CPR) (including cardioversion);
• Patients who have already received thrombolytic therapy;
• Prior myocardial infarction or coronary artery bypass surgery;
• Known serious hepatic, renal, blood, respiratory, or neuropsychiatric diseases;
• Malignant tumor, lymphoma, HIV-positive, or hepatitis;
• Uncontrolled hypertension (systolic BP >160 mm Hg or a diastolic BP >100 mmHg on at least two consecutive readings);
• Patients with active bleeding, major surgery or trauma within 3 months and cerebrovascular accident within 6 months;
• History of anemia (hemoglobin<90g/L) or thrombocytopenia (thrombocyte<90×109/L);
• Multi-vessel disease with non-culprit vessel intervention;
• Breastfeeding, pregnant, or potentially fertile women;
• Patients who have known to be allergic to Shenfu Injection or its components or patients with serious adverse effect;
• Patients with potential contraindication to CMR;
• Participation in other clinical trial in recent 3 months;
• Patients who cannot complete this trial or comply with the protocol.